Loading...
•
Dec 31, 2022
DexCom Q4 2022 Earnings Report
Reported financial results for the quarter and fiscal year ended December 31, 2022.
Key Takeaways
Dexcom's Q4 2022 revenue grew by 17% to $815.2 million compared to the same quarter of the prior year. GAAP operating income was $125.4 million, or 15.4% of revenue, and GAAP net income was $91.8 million, or $0.22 per diluted share.
Revenue grew 17% versus the same quarter of the prior year to $815.2 million.
U.S. revenue growth of 17% and international revenue growth of 15%.
GAAP operating income of $125.4 million or 15.4% of revenue, an increase of 1,530 basis points compared to the fourth quarter of 2021.
Received FDA clearance for the Dexcom G7 CGM system for people with diabetes ages two years and older.
DexCom
DexCom
DexCom Revenue by Segment
DexCom Revenue by Geographic Location
Revenue by Segment
Sensor and other Revenue
CapyFin.comHardware Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
The company is reiterating guidance for fiscal year 2023 revenue, Non-GAAP Gross Profit Margin, and Non-GAAP Operating Margin, and establishing guidance for Adjusted EBITDA Margin at the following levels:
Positive Outlook
- Revenue of approximately $3.35 - 3.49 billion (15-20% growth)
- Non-GAAP Gross Profit Margin of 62-63%
- Non-GAAP Operating Margin of approximately 16.5%
- Adjusted EBITDA Margin of approximately 26%
Revenue & Expenses
Visualization of income flow from segment revenue to net income